Accelerating Patient Access to Early and Affordable Detection and Surveillance Tests

The 2nd Liquid Biopsy Surveillance and Early Detection Summit returns as industry’s only meeting showcasing biopharma-led case studies and assay developer technical progress to create a commercially viable path forward for non-invasive testing to support early disease pipeline progress.

Ensure your whole team stays connected and ahead of the curve with unmatched industry insights across key challenges in scaling sensitive assays that enable earlier detection and utilizing ctDNA as a surrogate biomarker to improve surveillance for a paradigm shift towards achieving personalized treatment options.

Uniting patients, diagnostics and drug developers, this meeting is your one and only opportunity to learn about the latest advancements in liquid biopsy detection and early surveillance in oncology, neurology and rare disease, and how they can be implemented into clinical trials and in healthy populations.

DATES & VENUE
07 Nov - 09 Nov 2023, 9:00 am - 6:00 pm
#_REVIEWS

OTHER INFORMATION
Go to Event Website
Ticket pricing starts from:
Drug Developers and Academics Conference Pass: USD 0.50, Vendors Conference Pass: USD 3799.00
TOPICS | CATEGORIES






Advertisements